Uses | • rheumatoid arthritis • inflammatory bowel disease (Crohn disease; ulcerative colitis) |
Contraindications, drug interactions or cautions | Contraindications • hypersensitivity to adalimumab, tuberculosis, opportunistic infection, sepsis, moderate-to-severe heart failure (NYHA class III/IV) Drug interactions • abatacept, belimumab, certolizumab, infliximab, natalizumab, tacrolimus Cautions • patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to therapy. • treatment of latent tuberculosis should be initiated before use. |
Adverse Effects (common and severe) | • headache • skin rash • upper respiatory tract infection • sinusitis • tuberculosis • malignancy |
Instructions and dose (initial; typical) | indication-specific dosing (rheumatoid arthritis: 40 mg every other week subcutaneously; inflammatory bowel disease: 160 mg given as four 40 mg injections on day 1 or given as two 40 mg injections per day over 2 consecutive days) |
Monitoring | • signs and symptoms of active infection (including tuberculosis) • complete blood count with differential • signs/symptoms/worsening of heart failure |
Source of Suggestion | Commonly prescribed medication (Added on August, 2016) |